NICH yields 333333.33% · ABBV yields 3.09%● Live data
📍 NICH pulled ahead of the other in Year 1
Combined, NICH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NICH + ABBV for your $10,000?
Nitches Inc. wholesales, imports, and distributes clothing and home decor products under its own brand labels and retailer-owned private labels in the United States. It distributes clothing primarily in three categories: women's sleepwear and loungewear, women's sportswear and outerwear, and men's casual wear and performance apparel. The company markets women's sleepwear and loungewear under Princesse tam tam, Derek Rose, Crabtree & Evelyn, Disney Couture, The Anne Lewin Collection, The Claire Murray Collection, and Gossard brands; women's sportswear and outerwear under Adobe Rose, Country Tease, Saguaro, and Southwest Canyon brands; and men's casual wear and performance apparel under Nat Nast, Newport Blue, Dockers, The Skins Game, and ZOIC brands. In addition, it distributes made-to-order candles, candle holders, and other home decorating accessories under the Bill Blass and Newport Blue brands. It sells its branded products to department stores, specialty boutiques, moderate department stores, and national and regional discount department stores and chains; and private label products for retailers and catalogs. It sells its products through a sales network consisting of both in-house sales personnel and independent sale representatives. Nitches Inc. was formerly known as Beebas Creations Inc. and changed its name to Nitches Inc. in July 1992. The company was founded in 1971 and is based in Las Vegas, California.
Full NICH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.